Lithium addition in antidepressant-resistant depression:: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration

被引:9
作者
Birkenhager, Tom K.
van den Broek, Walter W.
Fekkes, Durk
Mulder, Paul G.
Moleman, Peter
Bruijn, Jan A.
机构
[1] Erasmus MC, Dept Psychiat, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands
[3] Erasmus MC, Dept Biostat & Epidemiol, Rootstown, OH USA
[4] Moleman Psychopharmacol, Amerongen, Netherlands
关键词
lithium addition; major depression; plasma; 5-HIAA; 5-HT; platelet;
D O I
10.1016/j.pnpbp.2007.03.012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The efficacy of the addition of lithium to an established course of antidepressant treatment can be explained by a synergistic effect of the two drugs on central 5-HT neurotransmission. In the present study we investigated the effect of lithium addition on the 5-HT concentration in plasma and platelets and the concentration of 5-HIAA. Thirty-nine depressed inpatients who fulfilled the DSM-IV criteria for major depressive disorder and who did not respond to monotherapy with either imipramine or fluvoxamine participated in this study. Concentration of 5-HT in both plasma and platelets did not change significantly during lithium addition. The 5-HT ratio (plasma concentration/platelet concentration) shows a small nonsignificant increase after 3 weeks lithium addition. The mean concentration of 5-HIAA shows a significant increase during lithium addition; with no difference between the imipramine and the fluvoxamine sample. The increments in 5-HIAA concentration during lithium addition are indicative of an increased 5-HT turnover. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1084 / 1088
页数:5
相关论文
共 22 条
[1]   Lithium augmentation in treatment-resistant-depression:: Meta-analysis of placebo-controlled studies [J].
Bauer, M ;
Döpfmer, S .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) :427-434
[2]   Lithium Augmentation Therapy in Refractory Depression: Clinical Evidence and Neurobiological Mechanisms [J].
Bauer, Michael ;
Adli, Mazda ;
Baethge, Christopher ;
Berghoefer, Anne ;
Sasse, Johanna ;
Heinz, Andreas ;
Bschor, Tom .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (07) :440-448
[3]   Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder [J].
Birkenhäger, TK ;
van den Broek, WW ;
Mulder, PG ;
Bruijn, JA ;
Moleman, P .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (11) :2060-2065
[4]   SHORT-TERM LITHIUM ADMINISTRATION ENHANCES SEROTONERGIC NEUROTRANSMISSION - ELECTROPHYSIOLOGICAL EVIDENCE IN THE RAT CNS [J].
BLIER, P ;
DEMONTIGNY, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 113 (01) :69-77
[5]   Hypotension caused by extracorporeal circulation - Serotonin from pump-activated platelets triggers nitric oxide release [J].
Borgdorff, P ;
Fekkes, D ;
Tangelder, GJ .
CIRCULATION, 2002, 106 (20) :2588-2593
[6]   EFFECTS OF ACUTE AND CHRONIC TREATMENT WITH FLUVOXAMINE ON EXTRACELLULAR AND PLATELET SEROTONIN IN THE BLOOD OF MAJOR DEPRESSIVE PATIENTS - RELATIONSHIP TO CLINICAL IMPROVEMENT [J].
CELADA, P ;
DOLERA, M ;
ALVAREZ, E ;
ARTIGAS, F .
JOURNAL OF AFFECTIVE DISORDERS, 1992, 25 (04) :243-250
[7]   LITHIUM INCREASES 5-HT-MEDIATED NEURO-ENDOCRINE RESPONSES IN TRICYCLIC RESISTANT DEPRESSION [J].
COWEN, PJ ;
MCCANCE, SL ;
COHEN, PR ;
JULIER, DL .
PSYCHOPHARMACOLOGY, 1989, 99 (02) :230-232
[8]   LITHIUM IN TRICYCLIC-RESISTANT DEPRESSION - CORRELATION OF INCREASED BRAIN 5-HT FUNCTION WITH CLINICAL OUTCOME [J].
COWEN, PJ ;
MCCANCE, SL ;
WARE, CJ ;
COHEN, PR ;
CHALMERS, JS ;
JULIER, DL .
BRITISH JOURNAL OF PSYCHIATRY, 1991, 159 :341-346
[9]   LITHIUM INDUCES RAPID RELIEF OF DEPRESSION IN TRICYCLIC ANTI-DEPRESSANT DRUG NON-RESPONDERS [J].
DEMONTIGNY, C ;
GRUNBERG, F ;
MAYER, A ;
DESCHENES, JP .
BRITISH JOURNAL OF PSYCHIATRY, 1981, 138 (MAR) :252-256
[10]   Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression [J].
Fekkes, D ;
Timmerman, L ;
Pepplinkhuizen, L .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (03) :235-239